3Boersma E, Harrington RA, Moliterno D J, et al. Platelet glycoprotein Ⅱ b/Ⅲ a inhibitors in acute coronary syndromes:a meta-analysis of all major randomised clinical trials.Lancet,359:189-198.
4Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention:results of the GOLD (AU-Assessing Ultegra) multicenter study.Circulation,2001,103:2572-2578.
5Batchelor WB, Tolleson TR, Huang Y, et al. Randomized comparison of platelet inhibition with abciximab,tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison of measurements of platelet aggregation with aggrastat,reopro,and eptifibatide.Circulation,2002,106:1470-1476.
6Topol EJ,Moliterno DJ,Herrmann HC,et al.Comparison of two platelet glycoprotein Ⅱ b/Ⅲa inhibitors,tirofiban and abciximab,for the prevention of ischemic events with percutaneous coronary revascularization.N Engl J Med,2001,344:1888-1894.
7Ernst NM,Suryapranata H,Miedema K,et al.Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.J Am Coll Cardiol,2004,44:1187-1193.
8Danzi GB,Sesana M,Capuano C,et al.Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function.Am J Cardiol,2004,94:35-39.
9Valgimigli M, Campo G,Percoco G,et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction:the multistrategy randomized trial.JAMA,2008,299:1788-1799.
10Valgimigli M,Percoco G,Malagutti P,et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction:a randomized trial.JAMA,2005,293:2109-2117.
